



Índice de intervenções por tema

B. IMAGING -> 03. IMAGING -> 03.1 ECHOCARDIOGRAPHY

- PO 71 MODERATE AORTIC STENOSIS: NOT AS BENIGN AS IT SEEMS
- PO 72 JOINING EFFORTS FOR THE NON-INVASIVE EVALUATION IN PULMONARY HYPERTENSION: TAPSE/SPAP RATIO
- PO 73 AUTOMATIC MULTI-VIEW POSE ESTIMATION IN FOCUSED CARDIAC ULTRASOUND
- PO 74 DIFFERENCES BETWEEN AL AND TRANSTHYRETIN CARDIAC AMYLOIDOSIS: A COMPARISON OF THE ECHOCARDIOGRAPHIC MORPHOLOGICAL VARIABLES
- PO 75 IS MYOCARDIAL FIBROSIS APPROPRIATELY ASSESSED BY 2D STRAIN DERIVED INTEGRATED BACKSCATTER?
- PO 131 FULLY AUTOMATED 3D ECHOCARDIOGRAPHIC ALGORITHMS: ACCURATE AND TIME SAVING - THE ANSWER FOR 3D IN ROUTINE CLINICAL PRACTICE?
- PO 132 AUTOMATIC QUALITY ASSESSMENT OF FOCUSED CARDIAC ULTRASOUND EXAMS
- PO 134 MYOCARDIAL WORK BY SPECKLE-TRACKING ECHOCARDIOGRAPHY IN PACEMAKER PATIENTS ACCORDING TO PACING SITE: A PROSPECTIVE STUDY
- CO 66 SPECKLE-TRACKING ECHOCARDIOGRAPHY FOR PREDICTION OF ADVERSE HEMODYNAMIC PARAMETERS IN HEART TRANSPLANT PATIENTS
- CO 131 LEFT ATRIAL AND LEFT VENTRICULAR STRAIN IMAGING EVALUATION OF HEART FAILURE WITH REDUCED EJECTION FRACTION PATIENTS UNDER SACUBITRIL/VALSARTAN: ATRIAL FIBRILLATION SUBSTUDY
- CO 132 LEFT ATRIAL STRAIN AND INTEGRATED BACKSCATTER: PREDICTORS OF RECURRENCE AFTER PAROXYSMAL, PERSISTENT, AND LONG-STANDING PERSISTENT ATRIAL FIBRILLATION CATHETER ABLATION
- CO 133 SERIAL GLOBAL AND LONGITUDINAL RV FUNCTIONAL ASSESSMENT IN SYMPTOMATIC, SEVERE AORTIC STENOSIS UNDERGOING AVR
- CO 134 WHAT HAPPENS TO MYOCARDIAL WORK AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT?
- CO 135 PROFILING RVOT SYSTOLIC FLOW MORPHOLOGY IN PRECAPILLARY PULMONARY HYPERTENSION
- CO 146 LEFT VENTRICULAR TWIST IN PATIENTS WITH SEVERE AORTIC STENOSIS: MEANING AND EVOLUTION AFTER SURGERY

B. IMAGING -> 03. IMAGING -> 03.2 COMPUTED TOMOGRAPHY

- PO 236 ASSOCIATION BETWEEN LEFT VENTRICULAR WALL-THICKNESS BY CT AND ENDOCARDIAL VOLTAGE POTENTIALS IN PATIENTS WITH ISCHEMIC CARDIOMYOPATHY
- PO 237 THE ROLE OF LIPIDS IN THE CALCIFICATION OF DIFFERENT CARDIAC STRUCTURES: A CARDIAC CT STUDY
- PO 239 INCIDENCE OF CORONARY ANOMALIES IN PATIENTS WITH D-TRANSPOSITION OF GREAT ARTERIES (D-TGA) AFTER ARTERIAL SWITCH OPERATION (ASO)
- PO 240 SCREENING OF THORACIC AORTIC CALCIFICATION BY COMPUTED TOMOGRAPHY FOR PREDICTING CLINICAL OUTCOMES IN PATIENTS UNDERGOING CARDIAC SURGERY
- CO 56 ASSOCIATION BETWEEN EPICARDIAL ADIPOSE TISSUE VOLUME AND RECURRENCE OF ATRIAL FIBRILLATION AFTER CATHETER ABLATION

- CO 116 COMPUTED TOMOGRAPHY-DERIVED MYOCARDIAL EXTRACELLULAR VOLUME IN PATIENTS WITH SEVERE AORTIC STENOSIS: CORRELATION WITH MARKERS OF VENTRICULAR DYSFUNCTION
- CO 117 A NOVEL MARKER OF CARDIOVASCULAR RISK STRATIFICATION: THE ROLE OF TOTAL CARDIOVASCULAR CALCIUM SCORE USING CARDIAC CT
- CO 118 CHOOSING BETWEEN CORONARY CT ANGIOGRAPHY AND FUNCTIONAL TESTS IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE - MIND THE (GENDER) GAP
- CO 119 ANGIOCT IN PULMONARY HYPERTENSION - SHOULD WE RENDER MULTIPLE VIEWS?
- CO 120 REPRODUCIBILITY OF EPICARDIAL ADIPOSE TISSUE RADIOMICS IN NON-CONTRAST COMPUTED TOMOGRAPHY
- CO 142 INFLUENCE OF AGE ON THE DIAGNOSTIC VALUE OF CORONARY ARTERY CALCIUM SCORE FOR RULING OUT CORONARY STENOSIS IN SYMPTOMATIC PATIENTS
- CO 145 CORONARY ARTERY CALCIUM IDENTIFIED ON NON-GATED CHEST CT SCANS - A WASTED OPPORTUNITY TO AVOID THE TRAGEDY
- CO 148 CORONARY ARTERY CALCIUM SCORE AS A GATEKEEPER FOR FURTHER TESTING IN PATIENTS WITH LOW PROBABILITY OF OBSTRUCTIVE CORONARY ARTERY DISEASE: A COST-EFFECTIVENESS ANALYSIS

B. IMAGING -> 03. IMAGING -> 03.3 CARDIAC MAGNETIC RESONANCE

- PO 172 MYOCARDIAL DEFORMATION IN ATHLETES MEASURED WITH FEATURE TRACKING CARDIOVASCULAR MAGNETIC RESONANCE
- PO 173 CARDIOVASCULAR MAGNETIC RESONANCE PREDICTORS FOR PULMONARY VALVE REPLACEMENT IN TETRALOGY OF FALLOT PATIENTS
- PO 175 MYOCARDIAL DEFORMATION AND MORPHOLOGICAL ADAPTATION TO EXERCISE IN ATHLETES: INSIGHTS FROM FEATURE TRACKING CARDIOVASCULAR MAGNETIC RESONANCE
 - CO 40 MYOCARDIAL SCAR CHARACTERISTICS BY 3D-LGE CANNOT FULLY EXPLAIN DIFFERENT ARRHYTHMIC EVENT RATES IN PRIMARY AND SECONDARY PREVENTION OF SUDDEN CARDIAC DEATH
- CO 106 HEPATIC T1 MAPPING: A NEW EASILY OBTAINED BIOMARKER FOR HEART FAILURE PATIENTS UNDERGOING CARDIAC MAGNETIC RESONANCE
- CO 107 CRITICAL APPRAISAL OF A NON-INVASIVE MODEL TO DERIVE PULMONARY CAPILLARY WEDGE PRESSURE FROM CARDIAC MAGNETIC RESONANCE IN HEART FAILURE PATIENTS - LOOK BEFORE YOU JUMP

B. IMAGING -> 03. IMAGING -> 03.4 NUCLEAR IMAGING

- PO 135 EXTRACARDIAC COMPLICATIONS IN INFECTIVE ENDOCARDITIS: THE ROLE OF 18-FDG-PET/CT
- PO 171 SHOULD WE PERFORM CARDIAC SCINTIGRAPHY WITH BONE TRACERS IN PATIENTS WITH IDIOPATHIC CARPAL TUNNEL? PRELIMINARY RESULTS OF CARPOS STUDY
- PO 174 UTILIZATION OF 18-FDG-PET/CT IN THE DIAGNOSIS OF NATIVE VALVE ENDOCARDITIS
- CO 108 UTILIZATION OF 18-FDG-PET/CT IN THE DIAGNOSIS OF PROSTHETIC VALVE ENDOCARDITIS
- CO 109 DIAGNOSTIC VALUE OF 18-FDG-PET/CT IN THE DIAGNOSIS OF CARDIAC IMPLANTABLE DEVICES

B. IMAGING -> 03. IMAGING -> 03.5 HYBRID AND FUSION IMAGING

- CO 110 AORTIC VALVE MICROCALCIFICATION ASSESSED BY 18F-SODIUM FLUORIDE POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY: IS THERE A LINK BETWEEN VALVE UPTAKE AND CARDIOVASCULAR RISK?
- CO 124 GLOBAL CARDIAC MICROCALCIFICATION ACTIVITY AS A MEASURE OF THE CARDIOVASCULAR RISK BURDEN: AN EXPLORATORY STUDY USING SODIUM FLUORIDE IN HIGH CARDIOVASCULAR RISK PATIENTS

B. IMAGING -> 03. IMAGING -> 03.7 IMAGING - OTHER

- PO 133 AUTOMATIC INTERPRETATION OF POINT-OF-CARE LUNG ULTRASOUND

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.2 ARRHYTHMIAS, GENERAL - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 100 DOES QT INTERVAL PROLONGATION HAVE PROGNOSTIC IMPLICATIONS IN TAKOTSUBO SYNDROME?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.3 ARRHYTHMIAS, GENERAL - DIAGNOSTIC METHODS

PO 44 NON-INVASIVE ELECTROCARDIOGRAPHIC MAPPING USING AN ENDO-EPICARDIAL SYSTEM SHOWS BETTER ACCURACY FOR ATRIAL ARRHYTHMIAS THAN VENTRICULAR ARRHYTHMIAS

CO 75 DIAGNOSTIC YIELD AND CLINICAL IMPLICATIONS OF IMPLANTABLE LOOP RECORDER FOR ARRHYTHMIA INVESTIGATION: A SINGLE CENTER EXPERIENCE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.6 ARRHYTHMIAS, GENERAL - CLINICAL

PO 140 SEVERITY OF OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH THE PRESENCE OF FREQUENT PREMATURE VENTRICULAR CONTRACTIONS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.1 ATRIAL FIBRILLATION - PATHOPHYSIOLOGY AND MECHANISMS

CO 57 LOW VOLTAGE AND LOW WAVE SPEED ARE RARELY PRESENT OUTSIDE THE LEFT ATRIUM-PULMONARY VEINS JUNCTION IN PAROXYSMAL ATRIAL FIBRILLATION BUT FREQUENTLY PRESENT IN PERSISTENT FORMS

CO 58 CHARACTERIZATION OF ROTOR PHENOMENA WITH HIGH-DENSITY BODY SURFACE ELECTRODE MAPPING IN PERSISTENT ATRIAL FIBRILLATION AND IMPACT OF PULMONARY VEIN ISOLATION

CO 59 UNDERSTANDING THE COMPLEX STRUCTURE OF THE LEFT ATRIUM FROM CARDIAC CT - A MACHINE LEARNING-BASED RADIOMICS MODEL TO PREDICT POST-ABLATION RECURRENCE OF ATRIAL FIBRILLATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.2 ATRIAL FIBRILLATION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 4 IMPACT OF OBSTRUCTIVE SLEEP APNOEA ON LONG-TERM ATRIAL FIBRILLATION-FREE SURVIVAL AFTER CATHETER ABLATION

PO 5 INVASIVE ATRIAL CONDUCTION INTERVAL AS A MARKER OF ATRIAL DISEASE AND AN INSTRUMENT OF PREDICTING ATRIAL FIBRILLATION RECURRENCE AFTER SUCCESSFUL CATHETER ABLATION

PO 163 A GLIMPSE AT THE MANAGEMENT OF ATRIAL FIBRILLATION - AN ASSESSMENT OF STANDARD OF CARE

CO 73 SEX DIFFERENCES IN TIME TO ATRIAL FIBRILLATION RECURRENCE AFTER CATHETER ABLATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.3 ATRIAL FIBRILLATION - DIAGNOSTIC METHODS

PO 2 VERY-EARLY DETECTION OF ATRIAL FIBRILLATION IN PATIENTS AFTER ABLATION EVALUATED BY A HOME-BASED WEARABLE ECG-PATCH

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.4 ATRIAL FIBRILLATION - TREATMENT

PO 3 CRYOABLATION: PROCEDURAL OUTCOMES FOR A SUCCESSFUL PULMONARY VEIN ISOLATION

PO 162 ARC-HBR SCORE PREDICTS BETTER THAN HEMORR2HAGES THE RISK OF MAJOR BLEEDING IN PATIENTS WITH ATRIAL FIBRILLATION

- PO 164 ANTIARRHYTHMIC PRE-TREATMENT AS A PREDICTOR OF SUCCESSFUL ELECTIVE ELECTRICAL CARIOVERSION OF ATRIAL FIBRILLATION
- PO 165 PREDICTORS IN PREVENTION OF ATRIAL FIBRILLATION RECURRENCE AFTER ELECTIVE ELECTRICAL CARIOVERSION
- CO 11 ATRIAL FIBRILLATION CATHETER ABLATION: ELECTROPORATION AGAINST HIGH-POWER SHORT DURATION RADIOFREQUENCY
- CO 13 VERY HIGH-POWER SHORT-DURATION VERSUS CONVENTIONAL RADIOFREQUENCY ABLATION GUIDED BY ABLATION INDEX FOR PULMONARY VEIN ISOLATION: DATA FROM A PORTUGUESE HEALTHCARE CENTRE
- CO 14 SINGLE VERSUS DOUBLE TRANSEPTAL PUNCTURE IN CATHETER ABLATION OF ATRIAL FIBRILLATION: CHARACTERIZATION AND LONG-TERM OUTCOMES IN A SINGLE TERTIARY CENTER
- CO 15 ATRIAL FIBRILLATION HIGH POWER RADIOFREQUENCY ABLATION: EFFICIENCY AND SAFETY

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.5 ATRIAL FIBRILLATION - STROKE PREVENTION

- PO 161 DIRECT ORAL ANTICOAGULANTS VERSUS VITAMIN K ANTAGONISTS AND NO ANTICOAGULATION IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION AND END-STAGE RENAL DISEASE OR HEMODIALYSIS
- CO 10 LOW-DOSE ORAL ANTICOAGULATION VERSUS DUAL ANTIPLATELET THERAPY FOLLOWED BY SINGLE ANTIPLATELET THERAPY IN PATIENTS SUBMITTED TO LEFT ATRIAL APPENDAGE OCCLUSION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.9 ATRIAL FIBRILLATION - OTHER

- PO 1 USE OF FLUOROSCOPY AND RADIATION EXPOSURE DURING AF ABLATION: A SINGLE-CENTER 10-YEAR EXPERIENCE.

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.2 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 43 PULMONARY VEIN ISOLATION WITH ADDITIONAL SUBSTRATE ABLATION FOR ATRIAL FIBRILLATION RESULTS IN AN INCREASED RISK FOR THE DEVELOPMENT OF ATYPICAL ATRIAL FLUTTER
- CO 72 PROCEDURAL RELATED VERSUS IDIOPATHIC ATYPICAL ATRIAL FLUTTER

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.3 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - DIAGNOSTIC METHODS

- CO 60 LEFT-SIDED ATYPICAL FLUTTER: A LOOK INTO THE MECHANISMS IN PATIENTS NOT SUBMITTED TO PRIOR LINEAR ABLATION
- CO 71 ATYPICAL FLUTTER: EFFECTIVENESS OF A SYSTEMATIC STRATEGY BASED ON COMPREHENSIVE HIGH-DENSITY MAP ANALYSIS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.4 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - TREATMENT

- PO 41 LONG TERM EFFECTIVENESS OF LEFT SIDED AFL ABLATION
- PO 42 CATHETER ABLATION FOR ATYPICAL ATRIAL FLUTTER: CHARACTERIZATION AND RECURRENCE PREDICTORS
- CO 12 CROSSING THE LINE IN PERIMITRAL FLUTTER ABLATION: A NEW SOLUTION FOR AN OLD PROBLEM

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.3 SYNCOPE AND BRADYCARDIA - DIAGNOSTIC METHODS

- PO 125 CAUGHT IN A LOOP: ONE CENTER'S EXPERIENCE WITH ILR

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.4 SYNCOPE AND BRADYCARDIA - TREATMENT

- PO 143 EFFECTIVENESS OF CARDIAC PACING IN THE PREVENTION OF NEUROCARDIOGENIC SYNCOPE IN PATIENTS WITH CARDIOINHIBITORY RESPONSE ON HEAD-UP TILT TEST
- PO 145 LEADLESS PACEMAKER: SINGLE CENTRE 5 YEAR EXPERIENCE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.2 VENTRICULAR ARRHYTHMIAS AND SCD - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 97 EXERCISE STRESS TEST IN BRUGADA SYNDROME - SHOULD WE RESTRICT PHYSICAL ACTIVITY?
- PO 98 FAMILY SCREENING FOR BRUGADA SYNDROME - ECG PARAMETERS AS A USEFUL SCREENING TOOL

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.3 VENTRICULAR ARRHYTHMIAS AND SCD - DIAGNOSTIC METHODS

- PO 99 AJMALINE PROVOCATIVE TEST IN THE DIAGNOSIS OF BRUGADA SYNDROME - WHAT TO EXPECT?
- CO 61 USING THE 3D ARCHITECTURE OF SCAR TO PREDICT LIFE-THREATENING VENTRICULAR ARRHYTHMIAS - STILL A LONG WAY TO GO

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.4 VENTRICULAR ARRHYTHMIAS AND SCD - TREATMENT

- PO 136 IMPACT OF A MULTIDISCIPLINARY APPROACH IN VENTRICULAR TACHYCARDIA ABLATION COMPLICATION RATE: TEAM WORK TO IMPROVE OUTCOMES
- PO 139 EFFECTIVENESS OF CATHETER ABLATION FOR TREATMENT OF SYMPTOMATIC FREQUENT PREMATURE VENTRICULAR COMPLEXES
- CO 62 EXTRACORPOREAL MEMBRANE OXYGENATION'S ROLE IN REFRACTORY ELECTRICAL STORM WITH NO STRAIGHTFORWARD TREATMENT - HOW MUCH TIME WORTHS?
- CO 63 NOVEL EPICARDIAL ACCESS TECHNIQUE FACILITATED BY CARBON DIOXIDE INSUFFLATION OF THE PERICARDIUM FOR ABLATION OF ARRHYTHMIAS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.5 VENTRICULAR ARRHYTHMIAS AND SCD - PREVENTION

- PO 96 OPTIMIZING ICD ROLE IN PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH - DOES MADIT-ICD BENEFIT SCORE HELPS IN A REAL-WORLD SETTING?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.1 ANTIBRADYCARDIA PACING

- PO 141 LEADLESS VS. TRANSVENOUS SINGLE-CHAMBER PACING - PROPENSITY-MATCHED COMPARISON OF OUTCOMES
- PO 142 RECURRENCE AFTER RESOLUTION OF SYMPTOMATIC ATRIOVENTRICULAR BLOCK AND CORRECTION OF TRANSIENT CAUSES - SHOULD WE KEEP AN EYE ON EVERYONE?
- PO 144 IMPLANTE DE PACEMAKER DEFINITIVO EM AMBULATÓRIO- UMA REALIDADE SEGURA E CUSTO-EFETIVA
- CO 38 ATRIOVENTRICULAR-SYNCHRONOUS LEADLESS PACEMAKERS: A SINGLE CENTER EXPERIENCE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.2 IMPLANTABLE CARDIOVERTER / DEFIBRILLATOR

- PO 122 QRS WIDTH VARIATION AS A MARKER OF PROGNOSIS AFTER CRT IMPLANTATION: GETTING SLIMMER IS GETTING BETTER!

- PO 137 SUBCUTANEOUS VERSUS TRANSVENOUS CARIOVERTER DEFIBRILLATOR: IMPROVED OUTCOMES IN MID-TERM FOLLOW-UP
- PO 138 LONG-TERM STABILITY OF ATRIAL SENSING IN IMPLANTABLE CARIOVERTER-DEFIBRILLATORS WITH FLOATING ATRIAL DIPOLE LEADS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.3 CARDIAC RESYNCHRONIZATION THERAPY

- PO 81 PROGNOSTIC IMPLICATIONS OF CRT RESPONSE CATEGORIZATION
- PO 82 PREDICTIVE FACTORS OF MORTALITY OR CLINICAL DETERIORATION IN ATRIAL FIBRILLATION PATIENTS RECEIVING CARDIAC RESYNCHRONIZATION THERAPY
- PO 83 IMPACT OF NON-TYPICAL LBBB ON CRT RESPONSE
- PO 85 HEART FAILURE CLINICAL OUTCOMES AFTER CARDIAC RESYNCHRONIZATION WITH QUADRIPOlar VERSUS BIPOLAR LEFT VENTRICULAR LEADS
- CO 36 LEFT BUNDLE BRANCH AREA PACING FOR ELECTRICAL SYNCHRONIZATION: DESCRIPTION OF A SINGLE-CENTER EXPERIENCE AND COMPARISON TO CONVENTIONAL BIVENTRICULAR PACING
- CO 37 LEFT BUNDLE BRANCH AREA PACING- FOLLOW UP DATA ON PACING PERFORMANCE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.4 HOME AND REMOTE PATIENT MONITORING

- CO 74 ECG-PATCH ASSESSMENT OF ATRIAL FIBRILLATION DURING THE VERY-EARLY BLANKING PREDICTS LATE BLANKING PERIOD RECURRENCE: PRELIMINARY DATA FROM A PROSPECTIVE REGISTRY

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.5 DEVICE COMPLICATIONS AND LEAD EXTRACTION

- PO 121 LEAD EXTRACTION USING THE PISA TECHNIQUE: COMPARISON OF NON-INFECTED VS INFECTED LEADS
- PO 123 PEDIATRIC CARDIAC PACING: TWENTY YEARS OF A SINGLE-CENTRE EXPERIENCE
- CO 39 LEAD EXTRACTION OF VERY OLD LEADS USING THE PISA TECHNIQUE - EXPERIENCE OF A PORTUGUESE TERTIARY CARE CENTER

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.6 DEVICE THERAPY - OTHER

- PO 45 PATIENTS WITH IMPLANTABLE CARDIAC DEVICES UNDERGOING RADIATION THERAPY: A SINGLE CENTER EXPERIENCE
- PO 84 PROGNOSTIC VALUE OF NUTRITIONAL STATUS IN POST-IMPLANT CRT OUTCOMES IN PATIENTS WITH CHRONIC HEART FAILURE
- PO 124 USEFULNESS OF DEVICE-DETECTED RESPIRATORY DISTURBANCE INDEX TO ASSESS CPAP THERAPY EFFICACY IN PATIENTS WITH SLEEP APNEA SYNDROME

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.2 CHRONIC HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 102 HEART FAILURE WITH RECOVERED LEFT VENTRICLE EJECTION FRACTION: CAN WE PREDICT IT?
- PO 103 ASSESSING THE FINAL YEAR OF HF PATIENTS BEFORE DEATH: WHY WE MUST STRIVE FOR BETTER END-OF-LIFE CARE
- PO 104 HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION IS NOT ALL ALIKE: THE IMPORTANCE OF DISEASE TRAJECTORY
- PO 126 A NEW PREDICTIVE SCORE TO EVALUATE THE IMPACT OF MALNUTRITION AND INFLAMMATION IN PATIENTS WITH HEART FAILURE - MAI-HF SCORE

- PO 127 PERFORMANCE OF THE MAGGIC SCORE IN PREDICTING ALL-CAUSE DEATH AND CARDIOVASCULAR EVENTS IN CORONARY HEART DISEASE PATIENTS
- PO 130 HEART FAILURE WITH PRESERVED EJECTION FRACTION AND CORONARY ARTERY DISEASE SUBPHENOTYPE: MORTALITY AND BIOMARKERS PROFILES ANALYSIS
- PO 205 ALCOHOL INTAKE AND CARDIAC REMODELING IN PATIENTS WITH ALCOHOLIC CARDIOMYOPATHY
 - CO 3 CLINICAL PHENOTYPES AND PROGNOSIS OF PATIENTS WITH HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION
 - CO 4 THE PROGNOSTIC IMPACT OF LOOP GAIN IN HEART FAILURE
- CO 86 CHANGES IN HEALTH-RELATED QUALITY OF LIFE AND TREATMENT EFFECTS IN CHRONIC HEART FAILURE: A META-ANALYSIS

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.3 CHRONIC HEART FAILURE - DIAGNOSTIC METHODS

- PO 203 FLUID CHALLENGE IN RIGHT HEART CATHETERISATION - A PROMISING APPROACH TO UNVEIL OCCULT HFPEF

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.4 CHRONIC HEART FAILURE - TREATMENT

- PO 101 HEART FAILURE EARLY POST DISCHARGE APPOINTMENT - A SINGLE CENTER EXPERIENCE
- PO 166 EFFECTS OF MAXIMUM DOSE SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION ACCORDING TO ATRIAL FIBRILLATION STATUS
- PO 169 OPTIMIZING HEART FAILURE MEDICAL THERAPY IN SECONDARY MITRAL REGURGITATION PATIENTS UNDERGOING TRANSCATHETER EDGE-TO-EDGE REPAIR
- PO 170 PHARMACOLOGIC TRANSITION IN THE CARE OF PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION - A REAL LIFE ANALYSIS
- PO 202 IMPACT OF ADVANCED CHRONIC KIDNEY DISEASE ON THERAPEUTIC MANAGEMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
 - CO 5 LONG-TERM OUTCOMES AFTER RESYNCHRONIZATION THERAPY: A DECADE OF EXPERIENCE FROM A SINGLE-CENTER
 - CO 87 EFFECTIVENESS AND SAFETY OF SACUBITRIL/VALSARTAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE - A REAL-WORLD EXPERIENCE
 - CO 88 ISCHEMIC AND NONISCHEMIC HEART FAILURE WITH REDUCED EJECTION FRACTION: ASSESSING LEFT ATRIAL STRAIN IMAGING AFTER SACUBITRIL/VALSARTAN THERAPY
 - CO 89 LEVOSIMENDAN - SINGLE CENTER EXPERIENCE WITH INTERMITTENT 24H ADMINISTRATION
 - CO 90 ATTR-CM IN A REAL-WORLD REFERRAL CENTER: A 3-YEAR EXPERIENCE DIAGNOSIS AND TREATMENT CHALLENGES

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.6 CHRONIC HEART FAILURE - CLINICAL

- PO 167 HEMODYNAMIC EFFECTS OF OUTPATIENT LEVOSIMENDAN INFUSION ASSESSED DAILY USING THE INVASIVE REMOTE MONITORING CARDIOMEMS™ SYSTEM
 - CO 2 INFLUENCE OF DIHYDROPYRIDINES CLASS OF CALCIUM CHANNEL BLOCKERS IN IRON DEFICIENCY IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.7 CHRONIC HEART FAILURE - OTHER

- PO 204 HEART FAILURE THERAPY COST AND ITS IMPACT ON MONTHLY INCOME IN THE PORTUGUESE POPULATION
 - CO 1 SCREENING FOR SLEEP BREATHING DISORDER IN PATIENTS WITH HEART FAILURE - 1 YEAR MULTIDISCIPLINARY TEAM EXPERIENCE

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.2 ACUTE HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 128 CYSTATIN C IS BETTER THAN CREATINE FOR PROGNOSTIC EVALUATION IN HEART FAILURE PATIENTS
- PO 129 DYNAMIC SCAI CLASSIFICATION DURING ADMISSION FOR CARDIOGENIC SHOCK - THE VALUE OF STAGING VARIATION IN THE FIRST 24 HOURS AND THE IMPACT OF RISK MODIFIERS

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.4 ACUTE HEART FAILURE- TREATMENT

- PO 105 HYPOALBUMINEMIA INCREASES THE TIME TO EUVOLEMIA IN HEART FAILURE PATIENTS
- PO 168 ELIGIBILITY FOR ACETAZOLAMIDE IN PATIENTS WITH DECOMPENSATED HEART FAILURE
- CO 20 VENO-ARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION FOR CARDIOGENIC SHOCK: ONE-YEAR OUTCOMES FROM A CARDIAC INTENSIVE CARE UNIT LED SHOCK TEAM PROGRAM

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.1 CORONARY ARTERY DISEASE - PATHOPHYSIOLOGY AND MECHANISMS

- CO 85 A BETTER UNDERSTANDING OF CORONARY ARTERY DISEASE MOLECULAR BIOLOGY THROUGH AN INTERMEDIATE PHENOTYPE

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.2 CORONARY ARTERY DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- CO 68 KEEPING TRACK OF CARDIAC ALLOGRAFT VASCULOPATHY IN THE 21ST CENTURY - A SINGLE-CENTER EXPERIENCE

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.3 CORONARY ARTERY DISEASE - DIAGNOSTIC METHODS

- PO 226 INVASIVE CORONARY FUNCTION TESTING IN PATIENTS WITH INOCA - A SINGLE CENTER EXPERIENCE
- CO 81 VALIDATION AND POTENTIAL USEFULNESS OF THE UPDATED PROMISE MINIMAL RISK TOOL IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE UNDERGOING CORONARY CT ANGIOGRAPHY
- CO 82 DETECTION OF CORONARY ARTERY DISEASE USING EPICARDIAL ADIPOSE TISSUE RADIOMICS IN NON-CONTRAST COMPUTED TOMOGRAPHY

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.4 CORONARY ARTERY DISEASE - TREATMENT

- CO 29 PERFORMANCE AND SAFETY OUTCOMES OF A STRUCTURED CHRONIC TOTAL OCCLUSION (CTO) PCI PROGRAM
- CO 84 ANGINA BEYOND STRUCTURAL CORONARY DISEASE: TAILORING MEDICAL THERAPY USING CORONARY FUNCTION TESTING

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.6 CORONARY ARTERY DISEASE - CLINICAL

- PO 235 CLINICAL AND LONG-TERM PROGNOSTIC TRENDS IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A MULTICENTRE NATIONAL REGISTRY ANALYSIS

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.1 ACUTE CORONARY SYNDROMES - PATHOPHYSIOLOGY
AND MECHANISMS**

PO 215 MINOCA - NOT A DEFINITIVE DIAGNOSIS

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.2 ACUTE CORONARY SYNDROMES - EPIDEMIOLOGY,
PROGNOSIS, OUTCOME**

PO 10 LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AFTER ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: LONG-TERM
CANCER INCIDENCE AND MORTALITY

PO 29 EXTERNAL VALIDATION OF A CLINICAL SCORE IN PREDICTING INTRAHOSPITAL DEATH IN MYOCARDIAL INFARCTION:
THE KASH SCORE

PO 66 RE-INFARCTION DURING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION: PREVALENCE, PREDICTORS
AND IMPACT ON MORTALITY

PO 69 ANTERIOR VERSUS NON-ANTERIOR STEMI: INCIDENCE OF REINFARCTION AND ALL-CAUSE MORTALITY AT LONG-TERM
FOLLOW-UP

PO 70 ELAPSED TIME FROM SYMPTOM ONSET TO CORONARY PERCUTANEOUS REVASCULARIZATION IN ACUTE CORONARY
SYNDROMES: IS THERE A GENDER DIFFERENCE?

PO 87 SPONTANEOUS CORONARY ARTERY DISSECTION: A 5-YEAR REVIEW FROM A TERTIARY CARE CENTER

PO 89 PREMATURE MYOCARDIAL INFARCTION WITH ST ELEVATION- 10 YEARS OF EXPERIENCE

PO 90 PROGNOSTIC VALUE OF REMNANT CHOLESTEROL LEVELS AFTER ACUTE PHASE OF MYOCARDIAL INFARCTION

PO 156 OUTCOMES OF DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH ASPIRIN IN PRIMARY
PREVENTION

PO 157 IDENTIFICATION OF FAMILIAL HYPERCHOLESTEROLEMIA IN ACUTE CORONARY SYNDROME PATIENTS: ARE WE MISSING
THE MARK?

PO 158 CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN PATIENTS ADMITTED WITH MYOCARDIAL INFARCTION: IMPACT
ON THERAPY AND PROGNOSIS

PO 159 PROGNOSTIC IMPACT OF CHRONIC KIDNEY DISEASE IN ACUTE CORONARY SYNDROMES

PO 160 ACUTE ST SEGMENT ELEVATION MYOCARDIAL INFARCTION LEAVES NO-ONE BEHIND: A YOUNG POPULATION ANALYSIS

PO 212 DO CARDIOVASCULAR RISK FACTORS IMPACT THE MANAGEMENT OF MYOCARDIAL INFARCTION WITH NO OBSTRUCTIVE
CORONARY ATHEROSCLEROSIS PATIENTS?

PO 213 CAN GENDER PLAY A ROLE IN MYOCARDIAL INFARCTION WITH NO OBSTRUCTIVE CORONARY ATHEROSCLEROSIS?

PO 231 THE KASH ONE TRIAL - EARLY DISCHARGE IN MYOCARDIAL INFARCTION: PRELIMINARY RESULTS

PO 232 LONG-TERM FOLLOW-UP (12 YEARS) OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION SURVIVORS IN ACCORDANCE
TO WEIGHT: IS THERE AN OBESITY PARADOX?

PO 233 HOSPITAL DISCHARGE AFTER UNCOMPLICATED ST ELEVATION ACUTE MYOCARDIAL INFARCTION: HOW EARLY IS SAFE?

PO 234 LADIES FIRST: AWARENESS FOR THE RISK OF ADVERSE OUTCOMES OF FEMALE PATIENTS AFTER ST-SEGMENT ELEVATION
ACUTE CORONARY SYNDROME

CO 53 THE INFLUENCE OF WEATHER IN THE FORECASTING OF STEMI OCCURRENCE

CO 54 COMPLETE REVASCULARIZATION VS CULPRIT-ONLY PCI IN STEMI PATIENTS WITH MULTIVESSEL DISEASE: A LONG-TERM
FOLLOW-UP ANALYSIS (8 YEARS) OF REINFARCTION AND ALL-CAUSE MORTALITY

CO 55 SEQUENTIAL KASH SCORE EVALUATION RESULTS IN NEAR PERFECT MORTALITY RISK PREDICTION IN ACUTE
MYOCARDIAL INFARCTION

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.3 ACUTE CORONARY SYNDROMES - DIAGNOSTIC METHODS**

PO 88 CAN WE PREDICT WHICH MYOCARDIAL INFARCTION WITH NO OBSTRUCTIVE CORONARY ATHEROSCLEROSIS PATIENTS
WILL REMAIN WITH UNEXPLAINED CAUSE?

- PO 227** CORONARY ANGIOGRAPHY AFTER OUT-OF-HOSPITAL CARDIAC ARREST WITHOUT ST-SEGMENT ELEVATION: IS IT TIME TO COOL DOWN?
- PO 229** CLINICAL TRENDS IN UNSTABLE ANGINA AFTER HIGH-SENSITIVE CARDIAC TROPONIN INTRODUCTION: A SINGLE CENTRE ANALYSIS

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->

13. ACUTE CORONARY SYNDROMES -> 13.4 ACUTE CORONARY SYNDROMES - TREATMENT

- PO 26** PREVIOUS USE OF AMIODARONE AND ITS EFFECT ON ARRHYTHMIC EVENTS AND OUTCOMES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
- PO 67** ARE THE RESULTS OF THE COMPLETE TRIAL APPLICABLE TO ALL ACUTE CORONARY SYNDROMES?
- PO 176** NSTE-ACS DUAL ANTIPLATELET PRE-TREATMENT: THE PORTUGUESE EXPERIENCE
- PO 177** DUAL ANTIPLATELET THERAPY DURATION IN PATIENTS WITH ACUTE CORONARY SYNDROME TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: HOW DO WE MAKE DECISIONS?
- PO 178** MINERALOCORTICOID RECEPTOR ANTAGONISTS AFTER ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH MILDLY REDUCED LEFT VENTRICULAR EJECTION FRACTION
- PO 179** EFFICACY AND SAFETY OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ELDERLY PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
- PO 180** ANTITHROMBOTIC THERAPY IN STEMI: EFFICACY AND SAFETY OF ADDING PARENTERAL ANTICOAGULATION IN STEMI UNDERGOING PCI
- PO 211** LONG TERM PROGNOSIS OF PHARMACOLOGICAL INTERVENTION IN MYOCARDIAL INFARCTION WITH NONOBSTRUCTIVE CORONARY ARTERIES (MINOCA)
- PO 230** CORONARY ASPIRATION THROMBECTOMY: NOT ALWAYS, NOT EVER
- CO 51** PRETREATMENT WITH PARENTERAL ANTICOAGULATION IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
- CO 52** SYSTEMATIC REVIEW AND META-ANALYSIS ON THE EFFICACY AND SAFETY OF P2Y12 INHIBITOR PRETREATMENT FOR PRIMARY PCI IN STEMI

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->

13. ACUTE CORONARY SYNDROMES -> 13.6 ACUTE CORONARY SYNDROMES - CLINICAL

- PO 68** PROGNOSIS OF PATIENTS WITH LEFT CIRCUMFLEX ARTERY-RELATED MYOCARDIAL INFARCTION BASED ON THE RESULTS OF A LARGE NATIONAL REGISTRY

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->

13. ACUTE CORONARY SYNDROMES -> 13.7 ACUTE CORONARY SYNDROMES - OTHER

- PO 86** PERCEIVED STRESS IN MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES?
- PO 214** STUDY OF THE PREVALENCE, PROGNOSIS AND MORTALITY OF PATIENTS DIAGNOSED WITH MINOCA
- PO 228** THE ROLE OF CARDIAC REHABILITATION IN PATIENTS FOLLOWING ACUTE CORONARY SYNDROME IN PORTUGAL - ARE WE DOING ENOUGH?

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->

14. ACUTE CARDIAC CARE -> 14.3 ACUTE CARDIAC CARE - CCU, INTENSIVE, AND CRITICAL CARDIOVASCULAR CARE

- PO 27** A VERY LONG STORY: INTRA-AORTIC BALLOON PUMP (IABP) COUNTERPULSATION IN PATIENTS WITH ACUTE CORONARY SYNDROME - A 18-YEARS SINGLE-CENTER EXPERIENCE
- CO 17** THE PORTUGUESE APPROACH TO CARDIOGENIC SHOCK IN ACUTE CORONARY SYNDROME
- CO 18** PREDICTION OF IN-HOSPITAL MORTALITY IN PATIENTS ADMITTED FOR CARDIOGENIC SHOCK TREATED WITH VA-ECMO - VALIDATION OF SAVE SCORE AND THE INCREMENTAL VALUE OF SERUM LACTATE

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->

14. ACUTE CARDIAC CARE -> 14.4 ACUTE CARDIAC CARE - CARDIOGENIC SHOCK

- PO 28 IABP IN CARDIOGENIC SHOCK - AFTERMATH 10 YEARS APART FROM IABP-SHOCK TRIAL
- PO 30 THE IMPORTANCE OF CONGESTION ASSESSMENT BY RIGHT HEART CATHETERIZATION IN CARDIOGENIC SHOCK PATIENTS
- CO 16 PREDICTORS OF IN-HOSPITAL MORTALITY IN MYOCARDIAL INFARCTION PRESENTING WITH CARDIOGENIC SHOCK
- CO 19 CIRCULATORY POWER - A NEWLY DEVELOPED NON-INVASIVE DYNAMIC PARAMETER TO PREDICT IN-HOSPITAL MORTALITY IN CARDIOGENIC SHOCK

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

15. VALVULAR HEART DISEASE -> 15.2 VALVULAR HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 56 PROGNOSTIC IMPACT OF LOW-FLOW CONDITIONS IN PERCUTANEOUS TREATMENT OF SEVERE AORTIC STENOSIS -A MATTER OF FLOW VERSUS VOLUME
- PO 57 PROGNOSTIC IMPLICATIONS OF AORTIC STENOSIS PROGRESSION RATE
- PO 181 IMPACT OF TRANSCATHETER AORTIC VALVE IMPLANTATION ON KIDNEY FUNCTION IN CHRONIC KIDNEY DISEASE PATIENTS
- PO 183 THE ROLE OF THE RIGHT HEART ON OUTCOMES AFTER TAVI: ANALYSIS FROM A LARGE SINGLE-CENTER COHORT
- CO 92 TELEMONITORING AORTIC VALVULAR INTERVENTION WAITING LIST PATIENTS PROGNOSTIC VALUE
- CO 136 DEFINING A PROGNOSTICALLY RELEVANT THRESHOLD FOR STROKE VOLUME INDEX IN SEVERE AORTIC STENOSIS PATIENTS UNDERGOING TRANSCATHETER VALVE IMPLANTATION

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

15. VALVULAR HEART DISEASE -> 15.3 VALVULAR HEART DISEASE - DIAGNOSTIC METHODS

- PO 58 ANOTHER WAY TO STUDY RISK FACTORS FOR AORTIC VALVE CALCIFICATION
- CO 137 CARDIAC DAMAGE EXTENT IN PATIENT WITH ISOLATED SEVERE AORTIC STENOSIS REFERRED TO SURGICAL AORTIC VALVE REPLACEMENT: IS IT REVERSIBLE AFTER SURGERY?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

15. VALVULAR HEART DISEASE -> 15.4 VALVULAR HEART DISEASE - TREATMENT

- PO 24 TEN YEARS FOLLOW-UP AFTER AORTIC VALVE REPLACEMENT WITH BIOPROSTHESIS TRIFECTA: A SINGLE CENTER RETROSPECTIVE COHORT
- PO 25 FREEDOM SOLO STENTLESS BIOPROSTHESIS FOR AORTIC VALVE REPLACEMENT - CLINICAL AND HEMODYNAMIC EVALUATION THROUGH SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 60 OUTCOMES AFTER TRANSCATHETER EDGE-TO-EDGE REPAIR OF PRIMARY MITRAL REGURGITATION - A SINGLE-CENTRE EXPERIENCE
- PO 184 UNILATERAL FEMORAL ACCESS FOR TRANSCATHETER AORTIC VALVE IMPLANTATION

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

16. INFECTIVE ENDOCARDITIS -> 16.2 INFECTIVE ENDOCARDITIS - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 76 PERFIL MICROBIOLÓGICO NA ENDOCARDITE INFECIOSA: ONDE ESTAMOS?
- PO 77 AZSHES SCORE: A NOVEL SIMPLIFIED RISK SCORE FOR PREDICTING IN-HOSPITAL MORTALITY IN INFECTIVE ENDOCARDITIS
- PO 78 PREDICTORS OF EARLY MORTALITY IN INFECTIVE ENDOCARDITIS - A SIX-YEAR SINGLE-CENTRE RETROSPECTIVE STUDY
- PO 79 CHOQUE NA ENDOCARDITE INFECIOSA
- PO 80 LONG-TERM TEMPORAL AND SEASONAL TRENDS OF INFECTIVE ENDOCARDITIS
- CO 138 TRANSCATHETER AORTIC VALVE IMPLANTATION INFECTIVE ENDOCARDITIS CHARACTERIZATION AND OUTCOMES

CO 139 IN-HOSPITAL MORTALITY IN INFECTIVE ENDOCARDITIS: A SCORE COMPARISON

CO 140 A LIGHT AT THE END OF THE TUNNEL - COULD INFECTIVE ENDOCARDITIS EPIDEMIOLOGY AND BURDEN BE CHANGING FOR THE BETTER?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
16. INFECTIVE ENDOCARDITIS -> 16.4 INFECTIVE ENDOCARDITIS - TREATMENT**

PO 22 SURGICAL VERSUS MEDICAL THERAPY IN PATIENTS WITH INFECTIVE ENDOCARDITIS AND SURGERY INDICATION: A RETROSPECTIVE STUDY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.1 MYOCARDIAL DISEASE - PATHOPHYSIOLOGY AND MECHANISMS**

PO 64 TAKOTSUBO SYNDROME - DIFFERENT TRIGGERS IN DIFFERENT POPULATIONS?

PO 155 UNDERSTANDING THE COMPLEX PHENOTYPE OF HYPERTROPHIC CARDIOMYOPATHY: THE ROLE OF SYSTEMIC INFLAMMATION

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.2 MYOCARDIAL DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

PO 59 SCREENING FOR CARDIAC AMYLOIDOSIS IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)

PO 62 MYOCARDITIS ASSOCIATED WITH SARS-COV-2 INFECTION OR COVID-19 VACCINATION: A VERY RARE ADVERSE EVENT?

PO 63 THE PREDICTIVE ROLE OF RIGHT AND LEFT VENTRICULAR LONGITUDINAL STRAIN MEASURED BY TWO-DIMENSIONAL ECHOCARDIOGRAPHY IN WILD-TYPE TRANSTHYRETIN CARDIAC AMYLOIDOSIS

PO 65 LEFT BUNDLE BRANCH BLOCK CARDIOMYOPATHY - AN INTRIGUING AND DEFIANT ENTITY FROM DIAGNOSIS TO TREATMENT

PO 153 PREDICTORS OF LEFT VENTRICULAR DYSFUNCTION IN HYPERTROPHIC CARDIOMYOPATHY: RESULTS FROM A NATIONWIDE REGISTRY

PO 191 TAKOTSUBO SYNDROME - DOES TRIGGER MATTER?

PO 192 CLINICAL CHARACTERIZATION AND LONG-TERM FOLLOW-UP OF PATIENTS WITH TAKOTSUBO SYNDROME: 18-YEAR EXPERIENCE OF A PORTUGUESE TERTIARY CARE CENTER

PO 193 DELAYED RECOVERY OF LEFT VENTRICULAR EJECTION FRACTION IN TAKOTSUBO SYNDROME AS A PREDICTOR OF MAJOR ADVERSE CARDIOVASCULAR EVENTS

PO 194 TAKOTSUBO SYNDROME - IS THE TYPICAL TYPE THE REAL VILLAIN?

PO 195 TAKOTSUBO SYNDROME IN PATIENTS WITH HISTORY OF MALIGNANCY: CLINICAL FEATURES AND FOLLOW-UP

CO 102 PHENOTYPES AND NATURAL HISTORY OF TNNT2 GENE MUTATION CARRIERS WITH FAMILIAL HYPERTROPHIC CARDIOMYOPATHY: A LONG FOLLOW UP STUDY

CO 103 PERSISTING SYMPTOMS DESPITE OPTIMAL MEDICAL TREATMENT IN PATIENTS WITH OBSTRUCTIVE HCM NOT ELIGIBLE FOR SEPTAL REDUCTION THERAPY: INSIGHTS FROM AN INTERNATIONAL REGISTRY

CO 105 UNVEILING THE ROLE OF SYSTEMIC INFLAMMATION IN HYPERTROPHIC CARDIOMYOPATHY - A NEW PREDICTOR OF CARDIOVASCULAR EVENTS

CO 126 CARDIAC AMYLOIDOSIS SCREENING: STILL A LONG WAY TO GO

CO 130 CARDIOVASCULAR MAGNETIC RESONANCE IN NEUROMUSCULAR DISORDERS - LOOKING AHEAD

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.3 MYOCARDIAL DISEASE - DIAGNOSTIC METHODS**

PO 61 THE ROLE OF CARDIAC MAGNETIC RESONANCE ON THE DIAGNOSIS OF COVID-19 RELATED MYOCARDITIS

CO 104 ASSESSMENT OF MYOCARDIAL WORK IN SARCOMERE GENE MUTATION CARRIERS AND OVERT HYPERTROPHIC CARDIOMYOPATHY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.4 MYOCARDIAL DISEASE - TREATMENT**

- CO 101 OUTCOMES AND SAFETY OF DISOPYRAMIDE AND NADOLOL IN A COHORT OF HYPERTROPHIC CARDIOMYOPATHY PATIENTS
- CO 127 TRANSTHYRETIN-DIRECTED ANTISENSE OLIGONUCLEOTIDE THERAPY EFFECTS ON ATTRV MYOCARDIOPATHY - A SINGLE-CENTER EXPERIENCE
- CO 128 SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY - RESULTS FROM A PATIENT SERIES
- CO 129 BETA-BLOCKERS AND ANTIPLATELET THERAPY IN TAKOTSUBO SYNDROME - TO DO OR NOT TO DO?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.6 MYOCARDIAL DISEASE - CLINICAL**

- PO 151 A PILOT CHARACTERIZATION OF PATIENTS WITH LEFT VENTRICULAR ARRHYTHMOGENIC AND DILATED CARDIOMYOPATHY
- PO 152 THE RISK OF CARDIAC HOSPITALIZATION AND ARRHYTHMIAS IN PATIENTS WITH ARRHYTHMOGENIC AND DILATED CARDIOMYOPATHIES
- PO 154 FAMILIAL AMYLOID POLYNEUROPATHY: CARDIAC INVOLVEMENT IN LIVER TRANSPLANTED PATIENTS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.2 CONGENITAL HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- PO 17 LATE ATRIAL TACHYARRHYTHMIAS IN ADULT FONTAN PATIENTS
- PO 18 WORST PROGNOSIS RISK FACTORS IN TETRALOGY OF FALLOT
- PO 20 RASOPATIAS - QUEM VÊ CARAS, VÊ MUTAÇÕES? EXPERIÊNCIA DE UM CENTRO TERCIÁRIO
- CO 31 CHARACTERIZATION AND COMPARISON OF RHYTHM DISTURBANCES AFTER ATRIAL OR ARTERIAL SWITCH SURGERIES FOR DEXTRO-TRANSPOSITION OF THE GREAT ARTERIES - A LONG-TERM FOLLOW-UP STUDY
- CO 32 LONG-TERM FOLLOW-UP STUDY OF ADVERSE EVENTS AFTER ATRIAL OR ARTERIAL SWITCH SURGERIES FOR DEXTRO-TRANSPOSITION OF THE GREAT ARTERIES
- CO 35 EXTERNAL VALIDATION OF SURVIVAL PREDICTING SCORE IN REPAIRED TETRALOGY OF FALLOT: AN OPPORTUNITY TO IMPROVE

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.4 CONGENITAL HEART DISEASE - TREATMENT**

- PO 16 ATRIAL FLUTTER ABLATION IN CONGENITAL HEART DISEASE
- PO 113 HOLD THE DOOR: EXPERIENCE OF A NON-TERCIARY CENTRE IN PATENT FORAMEN OVALE CLOSURE
- PO 115 PERCUTANEOUS OCCLUSION OF VASCULAR MALFORMATIONS WITH PENUMBRA COILS
- CO 34 SURPASSING THE COMPLEX SUBSTRATE OF ACCESSORY PATHWAYS ABLATION IN EBSTEIN ANOMALY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.7 PEDIATRIC CARDIOLOGY**

- CO 33 PATHOPHYSIOLOGY OF REFLEX SYNCOPE RESPONSE: ROLE OF THE AUTONOMIC NERVOUS SYSTEM AND BAROREFLEX FUNCTION

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->

21.2 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 109 LONG-TERM SURVIVAL OUTCOMES AND BASELINE HEMODYNAMICS IN PATIENTS WITH PAH VERSUS CTEPH
- PO 110 CHRONIC THROMBOEMBOLIC PULMONARY DISEASE FROM PROXIMAL TO DISTAL: WHAT ARE THE DIFFERENCES?
- PO 186 CT-EP SCORE: A PREDICTIVE MODEL OF THE PROGNOSTIC VALUE OF CT PULMONARY ANGIOGRAPHY IN PATIENTS WITH ACUTE PULMONARY EMBOLISM
- PO 190 HYPONATREMIA AS A PREDICTOR OF SHORT-TERM MORTALITY IN PATIENTS WITH ACUTE PULMONARY EMBOLISM
- CO 48 A TALE OF A DEADLY DUO - ESTIMATING PROGNOSIS IN CTD ASSOCIATED PH
- CO 96 IN-HOSPITAL MORTALITY AND REPERFUSION RATE IN OCTAGENARIANS WITH HIGH-RISK PULMONARY EMBOLISM: A NATIONWIDE POPULATION-BASED COHORT STUDY IN PORTUGAL FROM 2010 TO 2018
- CO 97 CLINICAL, ECHOCARDIOGRAPHIC, ANALYTICAL AND IMAGING PARAMETERS: WHICH ARE THE MAIN PROGNOSTIC FACTORS IN HOSPITALIZED PATIENTS WITH ACUTE PULMONARY EMBOLISM?
- CO 100 PREVALENCE AND PREDICTORS OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION FOLLOWING SEVERE FORMS OF ACUTE PULMONARY EMBOLISM

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->

21.3 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - DIAGNOSTIC METHODS

- PO 107 STROKE VOLUME INDEX IN PULMONARY ARTERIAL HYPERTENSION: THE NEW KID ON THE BLOCK
- PO 108 NEW 2022 ESC/ERS DEFINITION OF PULMONARY HYPERTENSION. CAN WE RELY ON THE SAME NON-INVASIVE ECHOCARDIOGRAPHIC PARAMETERS?
- PO 187 STROKE VOLUME INDEX IN CHRONIC TROMBOEMBOLIC PULMONARY HYPERTENSION: MORE INFORMATION IS POWER?
- PO 189 PERFORMING UNDER PRESSURE: CARDIOPULMONARY VENTILATORY EFFICIENCY IN PATIENTS WITH PULMONARY HYPERTENSION
- CO 45 DIAGNOSTICAR PRECOCEMENTE A DOENÇA VASCULAR PULMONAR - PARA ALÉM DA AVALIAÇÃO EM REPOUSO
- CO 49 ABDOMINOPELVIC CT FOR CANCER SCREENING IN PATIENTS WITH UNPROVOKED PULMONARY EMBOLISM - A CLOSED DISCUSSION?
- CO 50 CTEPH: RELEVANCE OF THE NEW 2022 ESC/ERS DEFINITION OF PULMONARY HYPERTENSION AND IMPACT ON DIAGNOSIS ACCURACY BY RIGHT HEART CATHETERIZATION

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -> 21.4 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - TREATMENT

- PO 188 PROGNOSTIC RISK FACTORS IN CATHETER-DIRECTED THERAPIES IN INTERMEDIATE-HIGH RISK ACUTE PULMONARY EMBOLISM
- CO 46 BALLOON PULMONARY ANGIOPLASTY FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: 5 YEARS OF EXPERIENCE IN A PORTUGUESE PULMONARY HYPERTENSION REFERRAL CENTER
- CO 47 MORE OPTIONS FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION TREATMENT - BALLOON PULMONARY ANGIOPLASTY IS AFFIRMING IT'S ROLE
- CO 98 CATHETER-DIRECTED THERAPIES IMPACT ON INTERMEDIATE-HIGH- AND HIGH-RISK PULMONARY EMBOLISM PATIENTS

G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 22. AORTIC DISEASE ->

22.2 AORTIC DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 23 PREDICTORS OF IN-HOSPITAL MORTALITY IN TYPE A ACUTE AORTIC DISSECTION

G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 22. AORTIC DISEASE -> 22.4 AORTIC DISEASE - TREATMENT

- PO 21 OUTCOMES OF MODERATE STENOSIS IN BICUSPID AORTIC VALVE - SURGERY TO ALL?
- PO 182 MILDLY REDUCED AND REDUCED EJECTION FRACTION HEART FAILURE PATIENTS HAVE WORST OUTCOMES AFTER TRANSVALVULAR CATHETER AORTIC VALVE IMPLANTATION
- PO 238 CALCIUM SCORE A PREDICTOR OF HEART FAILURE IMPROVEMENT AFTER TRANSCATHETER AORTIC VALVULAR IMPLANTATION

G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 23. PERIPHERAL VASCULAR AND CEREBROVASCULAR DISEASE -> 23.2 PERIPHERAL VASCULAR AND CEREBROVASCULAR DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 224 PREVALENCE AND PREDICTORS OF PERIPHERAL ARTERY DISEASE IN HYPERTENSIVE INDIVIDUALS: RESULTS FROM A LOCAL CARDIOVASCULAR SCREENING EVENT

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.1 INVASIVE IMAGING AND FUNCTIONAL ASSESSMENT

- CO 30 CORONARY ANGIOGRAPHY AFTER OUT-OF-HOSPITAL CARDIAC ARREST WITHOUT ST-SEGMENT ELEVATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED TRIALS
- CO 149 INTRAVASCULAR IMAGING MODALITIES IN CORONARY INTERVENTION: INSIGHTS FROM 3D-PRINTED PHANTOM CORONARY MODELS

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.2 CORONARY INTERVENTION

- PO 51 TIMING OF INVASIVE STRATEGY IN NSTEMI-ACS AND CHRONIC KIDNEY DISEASE: COULD IT INFLUENCE THE OCCURRENCE OF ARRHYTHMIC AND PUMP FAILURE EVENTS?
- PO 54 OUTCOMES OF DIABETIC PATIENTS SUBMITTED TO CHRONIC TOTAL OCCLUSION PCI
- PO 55 HOW ARE INTERVENTIONAL CARDIOLOGISTS MAKING THEIR TREATMENT DECISIONS DURING INVASIVE CORONARY ANGIOGRAPHY?
- PO 116 STANLEY SCORE: A NEW PREDICTIVE MODEL OF 3-YEAR MAJOR ADVERSE CARDIAC EVENTS FOLLOWING "FULL METAL JACKET" USING NEW-GENERATION DRUG-ELUTING STENTS
- PO 117 CLINICAL BENEFIT OF RIGHT CORONARY ARTERY CHRONIC TOTAL OCCLUSION PCI
- PO 118 USE OF CATHETER-BASED LEFT VENTRICULAR ASSISTANCE DEVICES IN HIGH-RISK PCI: ON THE EDGE OF A NEW FRONTIER
- PO 119 PENETRANCE OF PHYSIOLOGY USE IN INVASIVE CORONARY ANGIOGRAPHY: A LESION-LEVEL EVALUATION
- PO 120 HAVING A CRUSH FOR DOUBLE KISSING: BIFURCATION TECHNIQUE PERFORMANCE AND OUTCOMES
- PO 150 UNPLANNED PERCUTANEOUS CORONARY INTERVENTION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- CO 26 ANTI-THROMBOTIC AND GLUCOSE LOWERING THERAPY IN DIABETIC PATIENTS UNDERGOING PCI: BASELINE INCLUSION DATA OF THE ARHEMIS MULTICENTRE REGISTRY
- CO 27 COMPARATIVE PERFORMANCE OF CONTEMPORARY STENTS IN 3D-PRINTED LEFT MAIN BIFURCATION SIMULATION MODELS
- CO 28 LONG-TERM OUTCOMES OF "FULL-METAL JACKET" PERCUTANEOUS CORONARY INTERVENTIONS: A SEVENTEEN-YEAR SINGLE-CENTRE EXPERIENCE

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.3 NON-CORONARY CARDIAC INTERVENTION

- PO 114 VALIDATION OF ROPE AND PASCAL SCORES IN A REAL-WORLD COHORT OF ADULT PATIENTS UNDERGOING PATENT FORAMEN OVALE CLOSURE: A RETROSPECTIVE STUDY
- PO 146 MANTA VASCULAR CLOSURE DEVICE AFTER TRANSFEMORAL TRANSCATHETER AORTIC VALVE IMPLANTATION: A UNIVERSAL CLOSURE FOR ALL PATIENTS

- PO 147 TRANSCATHETER AORTIC VALVE IMPLANTATION PERCUTANEOUS ALTERNATIVE ACCESS ROUTES OUTCOMES
- PO 148 PACEMAKER IMPLANTATION AND DEPENDENCY AFTER TAVI - A TERTIARY CENTER EXPERIENCE
- PO 149 TRANSCATHETER AORTIC VALVE IMPLANTATION IN PATIENTS WITH LARGE AORTIC ANNULUS: A SINGLE CENTRE EXPERIENCE
- PO 185 PREDICTORS OF CLINICAL OUTCOMES FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 207 PARAVALVULAR LEAKS AFTER TAVI: RISK FACTORS AND PROGNOSTIC IMPACT - A HIGH VOLUME SINGLE CENTRE EXPERIENCE
- PO 208 RISK OF PACEMAKER IMPLANTATION AFTER TAVI: NOT ALL SELF-EXPANDABLE VALVES ARE CREATED EQUAL
- PO 209 MANTA VERSUS PROGLIDE IN VASCULAR CLOSURE OF TRANSFEMORAL TAVI
- PO 210 PERCUTANEOUS BALLOON MITRAL VALVULOPLASTY RESULTS THROUGHOUT THE DECADES: MORE COMPLICATIONS AND LESS SUCCESS - ARE WE DEALING WITH MORE SEVERE CASES?
 - CO 6 20 YEAR-FOLLOW UP OF MITRAL STENOSIS PATIENTS AFTER PERCUTANEOUS VALVE COMMISSUROTOMY: INVASIVE TRANSMITRAL PRESSURE GRADIENT DIFERENTIAL AS A PREDICTOR OF EVENTS
 - CO 7 LONG-TERM FOLLOW-UP OF PERCUTANEOUS BALLOON MITRAL VALVULOPLASTY FOR RHEUMATIC MITRAL STENOSIS
 - CO 8 POST-PROCEDURAL MITRAL REGURGITATION AS AN INDEPENDENT PREDICTOR OF MORBIDITY AND MORTALITY OUTCOMES
 - CO 9 TRANSCATHETER MITRAL VALVE REPAIR AND ITS IMPACT ON REVERSE RIGHT VENTRICULAR REMODELLING
- CO 111 COMPARISON OF MORTALITY SCORES PERFORMANCE IN TRANSCATHETER AORTIC VALVE REPLACEMENT: SUITING UP TO PERCUTANEOUS INTERVENTION
- CO 112 OVERCOMING AGE BORDERS: TAVI FOR NONAGENARIANS - A SINGLE CENTER EXPERIENCE
- CO 115 WHEN VALVE NEEDS ELECTRICAL WIRES - ESTIMATING PACEMAKER IMPLANTATION AFTER TAVR
- CO 147 PRIORITIZE-TAVI SCORE - A NOVEL CLINICAL TOOL "PREDICTING MORTALITY OR URGENT TAVI" ON WAITING LIST

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.4 INTERVENTIONAL CARDIOLOGY - OTHER

- PO 111 PREDICTORS OF LEFT VENTRICULAR HYPERTROPHY AT LONG-TERM FOLLOW-UP AFTER EFFECTIVE STENT IMPLANTATION FOR AORTIC COARCTATION
- PO 112 SUCCESSFUL PERCUTANEOUS RE-PERMEABILIZATION OF FONTAN CIRCUIT WITH STENT IMPLANTATION AFTER CONDUIT THROMBOSIS
- PO 206 SYNCHRONOUS VERSUS STAGED CAROTID ARTERY STENTING AND CARDIAC SURGERY - A UNICENTRIC STUDY
 - CO 99 ACUTE AND MIDDLE-TERM OUTCOMES OF INTERMEDIATE-HIGH-RISK ACUTE PULMONARY EMBOLISM PATIENTS SUBMITTED TO CATHETER-BASED THERAPY - A SINGLE-CENTRE PILOT STUDY
- CO 113 AORTIC INSUFFICIENCY IN PATIENTS WITH AORTIC STENOSIS SUBMITTED TO TAVR: DOES IT INFLUENCE THE OUTCOME?
- CO 114 AF IN TAVR PATIENTS: DOUBLE TROUBLE MEANS DOUBLE CARE

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.1 CARDIOVASCULAR SURGERY - CORONARY ARTERIES

- PO 53 SEX IMPACT IS NOT CONSTANT OVER TIME AFTER CORONARY ARTERY BYPASS GRAFTING

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.8 CARDIOVASCULAR SURGERY - TRANSPLANTATION

- PO 14 SAFETY AND TOLERABILITY OF SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS IN HEART TRANSPLANT RECIPIENTS
- CO 69 ANTIBODY-MEDIATED REJECTION - A MAJOR COMPLICATION AFTER HEART TRANSPLANTATION
- CO 70 THE IMPACT ON THERAPEUTIC APPROACH AFTER CORONARY COMPUTED TOMOGRAPHY IN A HEART TRANSPLANT PATIENT POPULATION

I. HYPERTENSION -> 27. HYPERTENSION -> 27.2 HYPERTENSION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 93 PERIPHERAL PULSE WAVE VELOCITY AND HYPERTENSIVE RESPONSE TO EXERCISE IN PREDICTING DEVELOPMENT OF RESISTANT HYPERTENSION

I. HYPERTENSION -> 27. HYPERTENSION -> 27.5 HYPERTENSION - PREVENTION

PO 91 PREDICTIVE CAPACITY OF ESSENTIAL HYPERTENSION - FAMILY HISTORY AND GENETIC RISK SCORE

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.1 RISK FACTORS AND PREVENTION - EPIDEMIOLOGY

PO 223 GENETIC RISK SCORE AND EPICARDIAL ADIPOSE TISSUE: NEW TOOLS WITH IMPACT ON CARDIOVASCULAR RISK ASSESSMENT

CO 121 THE PREDICTIVE ABILITY OF THE NEW EUROPEAN SCORE2 IN PRIMARY PREVENTION OF AN ASYMPTOMATIC POPULATION

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.2 RISK FACTORS AND PREVENTION - CARDIOVASCULAR RISK ASSESSMENT

PO 95 ESTIMATION OF 10-YEAR RISK OF FATAL AND NON-FATAL CARDIOVASCULAR DISEASE IN A PORTUGUESE POPULATION

PO 218 A NEW RISK SCORE FROM THE RETROSPECTIVE ANALYSIS OF MAXIMAL WORKLOAD PREDICTORS OF SURVIVAL IN ISCHEMIC HEART DISEASE AT 10 YEARS: THE RAPID-10 SCORE

PO 221 CARDIOVASCULAR RISK RECLASSIFICATION: THE IMPACT OF THE NEW SCORE2/SCORE2-OP IN THE PORTUGUESE POPULATION

PO 225 DIFFERENCES IN 10-YEAR CARDIOVASCULAR RISK ESTIMATION USING SCORE AND SCORE2 RISK PREDICTION TOOLS: A MODERATE RISK COUNTRY POPULATION ANALYSIS

CO 141 CORONARY ARTERY CALCIUM SCORE IS A PREDICTIVE TOOL FOR CARDIOVASCULAR EVENTS IN AN ASYMPTOMATIC POPULATION

CO 144 "PROGNOSTIC CHANGE" OF ADDING CORONARY CALCIUM SCORE AND GENETIC RISK SCORE TO EUROPEAN SCORE2 IN A MODERATE RISK REGION

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.3 SECONDARY PREVENTION

PO 40 LDL LEVELS IN VERY HIGH CARDIOVASCULAR RISK PATIENTS - A CALL FOR INTENSIVE LIPID-LOWERING THERAPY

PO 94 CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AT VERY HIGH RISK

CO 122 ATTAINMENT OF LDL-CHOLESTEROL GOALS IN PATIENTS WITH PREVIOUS MYOCARDIAL INFARCTION: A REAL-WORLD CROSS-SECTIONAL ANALYSIS

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.6 OBESITY

PO 37 POLYMORPHISMS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ARE ASSOCIATED WITH OBESITY IN A PORTUGUESE POPULATION

PO 38 SYNERGISTIC EFFECT OF TWO VARIANTS OF THE ACE GENE ON THE APPEARANCE OF OBESITY IN A PORTUGUESE POPULATION

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.7 DIABETES AND THE HEART

PO 39 ASSOCIATION BETWEEN INTENSITY OF GLYCEMIC CONTROL WITH GLP-1 RECEPTOR AGONISTS AND RISK OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW AND META-REGRESSION

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.14 RISK FACTORS AND PREVENTION - OTHER

- PO 49 CARDIOVASCULAR PREVENTION AND CORONARY ARTERY DISEASE IN THE YOUNG - A SINGLE CENTRE ANALYSIS
- PO 92 BEHAVIORAL AND GENETIC RISK FACTORS ASSOCIATED WITH INCREASED ARTERIAL STIFFNESS
- CO 143 COULD A HIGH EPICARDIAL ADIPOSE TISSUE VOLUME INCREASE THE ABILITY OF THE CALCIUM SCORE TO DISCRIMINATE CARDIOVASCULAR EVENTS IN AN ASYMPTOMATIC POPULATION?

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.1 EXERCISE TESTING

- PO 216 VALIDATION OF AN AEROBIC FITNESS QUESTIONNAIRE IN A COHORT OF PORTUGUESE ADULT CARDIAC PATIENTS
- PO 217 CHRONOTROPISM IN CPET - IS INCOMPETENCE LIMITING FUNCTIONAL CAPACITY?

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.2 CARDIOVASCULAR REHABILITATION

- PO 36 CORONARY ARTERY DISEASE AND APOLIPOPROTEIN LEVELS: ANALYSIS OF PATIENTS REFERRED TO A CARDIAC REHABILITATION PROGRAM
- PO 196 IMPACT OF A CARDIAC REHABILITATION PROGRAM ON ANXIETY AND DEPRESSIVE SYMPTOMS ON PATIENTS WITH HEART FAILURE AND CORONARY ARTERY DISEASE
- PO 197 THE ROLE OF PEAK VO₂ IN PROGNOSIS IN PATIENTS UNDERGOING A CARDIAC REHABILITATION PROGRAM
- PO 198 PREDICTORS OF FUNCTIONAL IMPROVEMENT AFTER A PHASE II CARDIAC REHABILITATION PROGRAM: IS LEFT VENTRICULAR EJECTION FRACTION AT BASELINE A LIMITING FACTOR?
- PO 199 CARDIAC REHABILITATION - TACKLING VENTRICULAR REMODELING AND IMPROVING FUNCTIONAL CAPACITY
- PO 200 CARDIAC REHABILITATION PHASE 3 - WHO ARE THOSE WHO CONTINUE DOWN THE PATH?
- PO 219 IMPACT OF CARDIAC REHABILITATION ON HEART FAILURE ACROSS EJECTION FRACTION SPECTRUM
- PO 220 GENDER DISPARITIES IN CARDIAC REHABILITATION - ARE WE CONCEALING APPLES FROM EVE?
- CO 125 EFFECTS OF EXERCISE TRAINING ON CARDIAC TOXICITY MARKERS IN WOMEN WITH BREAST CANCER UNDERGOING CHEMOTHERAPY WITH ANTHRACYCLINE: A RANDOMIZED CONTROLLED TRIAL

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.2 CARDIOVASCULAR DISEASE IN WOMEN

- PO 13 SEX-BASED DIFFERENCES IN QUALITY OF LIFE DURING PHASE II OF A CARDIAC REHABILITATION PROGRAM - A RETROSPECTIVE OBSERVATIONAL STUDY
- CO 21 SEX DIFFERENCES AND OUTCOMES AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION IN SEVERE AORTIC STENOSIS - AN ANALYSIS OF 488 CASES
- CO 22 STRESS IN WOMEN: DOES IT PREDICT THE TYPE ACUTE CORONARY SYNDROME?
- CO 23 EFFECTIVENESS OF A CARDIAC REHABILITATION PROGRAM IN WOMEN WITH HEART FAILURE
- CO 24 CARDIOTOXICITY ASSESSMENT ACCORDING TO CURRENT CARDIO-ONCOLOGY GUIDELINES IN A POPULATION OF FEMALE BREAST CANCER PATIENTS

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.4 NON-CARDIAC SURGERY/PRE-SURGICAL ASSESSMENT

- PO 31 WHAT IS THE COST OF DISCUSSING PATIENTS IN HEART TEAM IN THE PORTUGUESE NATIONAL HEALTH SYSTEM?

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.5 CARDIOVASCULAR DISEASE IN THE ELDERLY

- PO 46 LONG-TERM PROGNOSIS OF ELDERLY PATIENTS UNDERGOING ATRIAL SEPTUM DEFECT CLOSURE: ARE WE ACTING TOO LATE?

- PO 47 CARDIAC REHABILITATION IN OLDER POPULATIONS - NEVER TOO LATE TO IMPROVE CV HEALTH
- PO 48 PROGNOSIS IN OLDEST ADULTS AFTER HOSPITALIZATION IN A CARDIAC INTENSE CARE UNIT - THE AGE PARADOX
- PO 52 IT'S NOT TOO LATE - PERCUTANEOUS ANGIOGRAPHY IN A 90-PLUS POPULATION

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.6 CARDIO-ONCOLOGY

- PO 6 RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY IN CANCER PATIENTS WITH HEART FAILURE
- PO 7 CARDIAC RESYNCHRONIZATION THERAPY IN ANTHRACYCLINE-INDUCED CARDIOMYOPATHY
- PO 8 CARDIOVASCULAR DETERMINANTS OF CHEMOTHERAPY SUSPENSION IN A COHORT OF PATIENTS WITH HIGH CARDIOVASCULAR RISK
- PO 9 THE BENEFICIAL ROLE OF CARDIOPROTECTIVE DRUGS IN PREVENTING CARDIOTOXICITY IN HER2 POSITIVE BREAST CANCER - AN ECHOCARDIOGRAPHIC POINT-OF-VIEW
- CO 25 RELATIONSHIP BETWEEN ECHOCARDIOGRAPHIC OUTCOMES AND CARDIOPROTECTIVE DRUGS IN A POPULATION OF FEMALE BREAST CANCER PATIENTS EXPOSED TO ANTHRACYCLINES
- CO 83 THE ROLE OF CARDIOVASCULAR RISK FACTORS IN CORONARY VASOSPASM WITH FLUOROPYRIMIDINES

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.7 PREGNANCY AND CARDIOVASCULAR DISEASE

- PO 11 WHEN A MOTHER'S HEART SUFFERS A LITTLE MORE THAN USUAL: A CENTER EXPERIENCE OF HEART DISEASE DURING PREGNANCY
- PO 12 PREGNANCY IN HIGH CARDIOVASCULAR RISK WOMEN: NOT ALWAYS A STATE OF GRACE
- CO 44 CARDIAC REMODELLING AND REVERSE REMODELLING IN PREGNANCY: WHAT IS THE IMPACT OF CARDIOVASCULAR RISK FACTORS?

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.14 CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS - OTHER

- PO 19 ADULTS' KNOWLEDGE AND PERCEPTION OF THEIR CONGENITAL HEART DISEASE: A SINGLE CENTER COSS-SECTIONAL STUDY
- PO 222 LDLR ACTIVITY IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA IN PORTUGAL
- CO 64 CAUSES OF SUDDEN DEATH IN A YOUNG (<40 YEARS OLD) SOUTH EUROPEAN POPULATION: A POSTMORTEM STUDY
- CO 65 IDIOPATHIC ISOLATED LEFT BUNDLE BRANCH BLOCK - A BENIGN FINDING OR SOMETHING MORE?
- CO 67 GLOBAL LONGITUDINAL STRAIN AND MYOCARDIAL WORK AS A NOVEL TOOL FOR ACUTE CELLULAR REJECTION PREDICTION IN HEART TRANSPLANT PATIENTS
- CO 123 CLINICAL AND GENETIC CHARACTERISTICS OF PATIENTS WITH A CLINICAL DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA IN PORTUGAL

L. CARDIOVASCULAR PHARMACOLOGY -> 31. PHARMACOLOGY AND PHARMACOTHERAPY -> 31.1 CARDIOVASCULAR PHARMACOTHERAPY

- CO 79 VARIABILITY OF THE ANTITHROMBOTIC EFFECT OF ACETYLSALICYLIC ACID WITH THE ADMINISTRATION OF DIFFERENT DOSAGES: REALITY OR MYTH?

M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.3 CARDIOVASCULAR NURSING - OTHER

- CO 41 THE INFLUENCE OF A NURSE-LED CARDIAC REHABILITATION PROGRAM ON QUALITY OF LIFE AND FUNCTIONAL CAPACITY OF PATIENTS WITH HEART FAILURE

CO 42 CAPACIDADE DE AUTOCUIDADO DOS DOENTES COM DIAGNÓSTICO DE INSUFICIÊNCIA CARDÍACA INTERNADOS NUM SERVIÇO DE CARDIOLOGIA

CO 43 HEALTH LITERACY IN HEART FAILURE - THE PORTUGUESE REALITY IN 2022

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY

-> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.3 COMPUTER MODELING AND SIMULATION

CO 150 DEVELOPMENT OF A MACHINE LEARNING MODEL USING 12-LEAD ECG TO IMPROVE ACUTE DIANOSIS OF PULMONARY EMBOLISM

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.4 DIGITAL HEALTH

PO 32 [SALUS] REMOTE MONITORING OF PHYSIOLOGIC PARAMETERS AND ASSESSMENT OF CARDIOVASCULAR PATIENTS

CO 93 ENHANCING THE EYES OF INTERVENTIONAL CARDIOLOGISTS: IMPACT OF ARTIFICIAL INTELLIGENCE IN OPERATOR ASSESSMENT OF CORONARY LESIONS

CO 94 DIGITAL PATIENT TOOL FOR REPORTING QUALITY OF LIFE AFTER ATRIAL FIBRILLATION CATHETER ABLATION: OUTCOMES FROM A PORTUGUESE HEALTHCARE CENTRE

CO 95 DIGITAL FOLLOW-UP PROGRAM FOR PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION: THE EXPERIENCE OF A PORTUGUESE CENTER

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 34. PUBLIC HEALTH AND HEALTH ECONOMICS -> 34.1 PUBLIC HEALTH

PO 33 DOES WATCHING SPORTS IMPACT YOUR HEART?

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 34. PUBLIC HEALTH AND HEALTH ECONOMICS -> 34.3 HEALTH ECONOMICS

PO 34 EFFECTIVENESS OF AN ELECTRONIC ALERT ON INAPPROPRIATE NT-PROBNP SHORT-TERM REPEAT TESTING

CO 91 THE WAITING 4 SURGERY STUDY - BURDEN OF IN-HOSPITAL CARE

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.3 BASIC SCIENCE - CARDIAC DISEASES

CO 80 KETONES' IMPACT ON A DYSMETABOLIC RAT MODEL OF HEART FAILURE WITH PRESERVED EJECTION FRACTION

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.6 BASIC SCIENCE - OTHER

CO 76 ZNF259 RS964184 GENETIC VARIANT IS ASSOCIATED WITH METABOLIC SYNDROME IN A PORTUGUESE POPULATION

CO 77 TCF21 GENE AND CARDIOVASCULAR EVENTS IN A CORONARY POPULATION

CO 78 IDENTIFYING PLASMA LIPID SIGNATURES FOR CARDIOVASCULAR RISK ASSESSMENT IN HFPEF PATIENTS

P. OTHER -> 37. MISCELLANEA

PO 15 THE WAITING 4 SURGERY STUDY - PREDICTION OF IN-HOSPITAL EVENTS

PO 35 3D- SIMULATOR TRAINING IN INTERVENTIONAL CARDIOLOGY: A POTENTIAL GAME CHANGER?

PO 106 INCIDENCE, PREVALENCE AND CLINICAL IMPACT OF SUPRAVENTRICULAR TACHYCARDIA IN GROUP I PULMONARY HYPERTENSION